Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NAZ2329 is the first cell-permeable inhibitor of the R5 subfamily of receptor-type protein tyrosine phosphatases (RPTPs), which is a variant and preferentially inhibits PTPRZ (IC50=7.5 μM for hPTPRZ1) and PTPRG (IC50=4.8 μM for hPTPRG) compared to other PTPs. NAZ2329 inhibited the tumor growth of glioblastoma cells and exhibited stem cell-like properties compared to the whole (D1 + D2) fragment of PTPRZ.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 1,400.00 | |
50 mg | 10-14 weeks | $ 1,820.00 | |
100 mg | 10-14 weeks | $ 2,820.00 |
Description | NAZ2329 is the first cell-permeable inhibitor of the R5 subfamily of receptor-type protein tyrosine phosphatases (RPTPs), which is a variant and preferentially inhibits PTPRZ (IC50=7.5 μM for hPTPRZ1) and PTPRG (IC50=4.8 μM for hPTPRG) compared to other PTPs. NAZ2329 inhibited the tumor growth of glioblastoma cells and exhibited stem cell-like properties compared to the whole (D1 + D2) fragment of PTPRZ. |
Molecular Weight | 501.56 |
Formula | C21H18F3NO4S3 |
CAS No. | 2809469-05-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NAZ2329 2809469-05-2 inhibitor inhibit